ZEGERID (omeprazole, sodium bicarbonate) by Salix Pharmaceuticals is proton pump inhibitors [moa]. Approved for sodium bicarbonate for oral suspension is indicated in adults for: reduction of risk of upper gastrointestinal (gi) bleeding in critically ill patients ( ). First approved in 2006.
Drug data last refreshed 23h ago · AI intelligence enriched 3w ago
ZEGERID is an oral capsule combining omeprazole (a proton pump inhibitor) with sodium bicarbonate, approved by the FDA on February 27, 2006. It functions by irreversibly inhibiting gastric acid secretion through blockade of the H+/K+-ATPase enzyme in parietal cells. The sodium bicarbonate component provides rapid acid neutralization, enabling faster omeprazole absorption compared to enteric-coated formulations alone. ZEGERID is indicated for acid-related gastrointestinal conditions and represents a branded alternative within the mature proton pump inhibitor class.
Proton Pump Inhibitors
Proton Pump Inhibitor
Phase III Study Comparing Zegerid® With Losec® for the Relief of Heartburn Associated With Gastroesophageal Reflux Disease
A Study to Compare Omeprazole Administered as Zegerid® Powder and as Prilosec® Capsule in Healthy Participants (P08050)(CL2010-12)
A Three-Period Study to Investigate the Relative Bioavailability and Pharmacodynamic Profiles of a Zegerid 20mg Capsule, Zegerid 20mg Powder for Oral Suspension and Losec 20mg Capsule in Healthy Adult Volunteers Under Fasting Conditions
A Pharmacodynamic Study Comparing Zegerid® and Prilosec OTC® (Study CL2008-02)(P07814)(COMPLETED)
A Pharmacodynamic Study Comparing Zegerid® and Prilosec OTC® (CL2007-17 )(P07813)(COMPLETED)
Worked on ZEGERID at Salix Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moZEGERID's approaching loss of exclusivity and minimal Part D market presence suggest very limited career opportunity within this product. Currently, zero linked job openings are recorded, indicating no active commercial expansion or staffing plans. Professionals interested in this product would likely focus on legacy brand management, trade marketing, or managed care contracting roles targeting the shrinking branded PPI segment rather than growth-oriented positions.